Eli Lilly & Co (LLY) - Revenue Change due to FX (I:ELCLMS4H)
Level Chart
Basic Info
|
Eli Lilly & Co (LLY) - Revenue Change due to FX is at 4.00%, compared to 1.00% last quarter and -2.00% last year. This is higher than the long term average of -0.15%. |
|
Revenue Change due to FX refers to the percentage change in the company's total revenue that is attributed to fluctuations in foreign exchange (FX) rates. This metric helps investors, analysts, and stakeholders understand the impact of changes in currency exchange rates on Eli Lilly & Co's overall revenue growth or decline. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 4.00% |
| Latest Period | Mar 2026 |
| Last Updated | May 20 2026, 18:19 EDT |
| Next Release | Aug 15 2026, 08:30 EDT (E) |
| Long Term Average | -0.15% |
| Average Growth Rate | -69.70% |
| Value from Last Quarter | 1.00% |
| Change from Last Quarter | 300.0% |
| Value from 1 Year Ago | -2.00% |
| Change from 1 Year Ago | N/A |
| Frequency | Quarterly |
| Unit | Percent |
| Adjustment | N/A |
| Download Source File |
Historical Data
| Date | Value |
|---|---|
| March 31, 2026 | 4.00% |
| December 31, 2025 | 1.00% |
| September 30, 2025 | 2.00% |
| June 30, 2025 | 1.00% |
| March 31, 2025 | -2.00% |
| December 31, 2024 | 0.00% |
| September 30, 2024 | -1.00% |
| June 30, 2024 | -1.00% |
| March 31, 2024 | 0.00% |
| December 31, 2023 | 1.00% |
| September 30, 2023 | 1.00% |
| June 30, 2023 | -1.00% |
| March 31, 2023 | -2.00% |
| Date | Value |
|---|---|
| December 31, 2022 | -4.00% |
| September 30, 2022 | -4.00% |
| June 30, 2022 | -3.00% |
| March 31, 2022 | -2.00% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 1.00% |
| June 30, 2021 | 3.00% |
| March 31, 2021 | 3.00% |
| December 31, 2020 | 1.00% |
| September 30, 2020 | 1.00% |
| June 30, 2020 | -1.00% |
| March 31, 2020 | -1.00% |
| December 31, 2019 | -1.00% |
News
Basic Info
|
Eli Lilly & Co (LLY) - Revenue Change due to FX is at 4.00%, compared to 1.00% last quarter and -2.00% last year. This is higher than the long term average of -0.15%. |
|
Revenue Change due to FX refers to the percentage change in the company's total revenue that is attributed to fluctuations in foreign exchange (FX) rates. This metric helps investors, analysts, and stakeholders understand the impact of changes in currency exchange rates on Eli Lilly & Co's overall revenue growth or decline. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 4.00% |
| Latest Period | Mar 2026 |
| Last Updated | May 20 2026, 18:19 EDT |
| Next Release | Aug 15 2026, 08:30 EDT (E) |
| Long Term Average | -0.15% |
| Average Growth Rate | -69.70% |
| Value from Last Quarter | 1.00% |
| Change from Last Quarter | 300.0% |
| Value from 1 Year Ago | -2.00% |
| Change from 1 Year Ago | N/A |
| Frequency | Quarterly |
| Unit | Percent |
| Adjustment | N/A |
| Download Source File |
Related Securities
Related Indicators
| Eli Lilly & Co (LLY) - Immunology Revenue | 1.203B USD |
| Eli Lilly & Co (LLY) - Neuroscience Revenue | 382.00M USD |